Skip to Content
Merck
  • Cardiogenic shock triggered by verapamil and atenolol: a case report of therapeutic experience with intravenous calcium.

Cardiogenic shock triggered by verapamil and atenolol: a case report of therapeutic experience with intravenous calcium.

Japanese circulation journal (2000-12-08)
H Sakurai, M Kei, K Matsubara, K Yokouchi, K Hattori, R Ichihashi, Y Hirakawa, H Tsukamoto, Y Saburi
ABSTRACT

Cardiogenic shock developed in a 72-year-old Japanese woman during combination therapy with verapamil and atenolol for recurrent supraventricular arrhythmia. She had coronary atherosclerosis, liver cirrhosis and bradycardia-tachycardia syndrome. Despite of the high-dose catecholamines and counterpulsation, she progressively deteriorated. Bolus administration of intravenous calcium chloride (CaCl2) immediately resolved her hemodynamic collapse.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Atenolol, ≥98% (TLC), powder
Supelco
Atenolol solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
USP
Atenolol, United States Pharmacopeia (USP) Reference Standard
Atenolol, European Pharmacopoeia (EP) Reference Standard